§ Legislative Act Oversight
Federal Research Integrity and Independence
Current Status
Existing Law: Federal Technology Transfer Act, 15 U.S.C. § 3710. Office of Research Integrity regulations (42 C.F.R. Part 93). Federal Advisory Committee Act, 5 U.S.C. App. 2. Ethics in Government Act, 5 U.S.C. App.
Current Authority: Office of Research Integrity (HHS) handles misconduct for PHS-funded research only. Agency-specific conflict-of-interest rules with inconsistent enforcement. Individual agencies investigate their own research integrity complaints.
Existing Limitations: Office of Research Integrity jurisdiction limited to PHS-funded research. No binding cooling-off periods for researchers (only voluntary guidelines). No prohibition on industry funding of regulatory science. No mandatory public health finding publication timelines.
Problem
Specific Harm: 47% of FDA advisory committee members report financial conflicts with affected industries¹. Average 3.2-year delay in publication of negative public health findings². Industry-funded studies 4x more likely to reach favorable conclusions³. No binding revolving door restrictions for federal researchers moving to regulated industries.
Who is Affected: Public health outcomes delayed by suppressed or delayed safety findings. Taxpayers funding research with undisclosed industry influence. Small businesses excluded from standards-setting dominated by large corporations. Whistleblowers facing retaliation with inconsistent protections across agencies.
Gaps in Current Law: No government-wide research integrity body. No binding publication timeline for public health findings. No prohibition on industry funding of research that informs regulatory decisions. No criminal penalties for research suppression.
Accountability Failures: Agencies self-investigate research integrity complaints (fox-guarding-henhouse). Office of Research Integrity limited to PHS-funded research. No public dashboard for conflict disclosures. Whistleblower protections inconsistently applied across agencies4.
Proposed Reform
Primary Policy Change: Establish government-wide research integrity standards with mandatory conflict disclosure, binding publication timelines for public health findings, complete separation of industry funding from regulatory science conclusions, and independent oversight through Court of Federal Claims.
New Requirements:
(1) Three-year revolving door restriction for federal researchers before employment with entities they regulated, funded, or evaluated. Restriction applies to GS-13 and above or equivalent. Criminal penalties for violations: up to 2 years imprisonment, $50,000 fine, and disgorgement of compensation received.
(2) Mandatory conflict of interest disclosure for all federal researchers and advisory committee members. Financial conflict threshold: $5,000 annually from affected entities. Equity holdings threshold: $10,000 in affected industries. Five-year lookback period for employment and consulting relationships.
(3) Public health findings publication timeline: preprint submission within 30 days of completion, peer-reviewed publication within 6 months. Data, methodology, and code deposit in public repositories within 60 days.
(4) Automatic publication trigger: if agency fails to publish public health finding within 30-day deadline, finding automatically releases to public repository 7 days later unless Court of Federal Claims grants specific extension for genuine national security.
(5) Industry funding prohibition: entities with financial interest in research outcomes may not fund, direct, or control research that informs regulatory decisions. Industry may fund research infrastructure but not research conclusions or priority-setting.
(6) Advisory committee reform: financially conflicted parties may participate as non-voting consultants only. Voting membership requires "independent scientist" certification (no funding, consulting, or employment from commercial entities in relevant field within preceding 5 years).
(7) Whistleblower protections: qui tam provisions for researchers reporting integrity violations (15-30% of recovered amounts). Direct access to Office of Special Counsel. Prohibition on retaliation with burden-shifting to agency after prima facie showing.
(8) GAO (GAO) exclusive jurisdiction over research integrity disputes, replacing agency self-investigation. GAO panels include at least one member with scientific research experience.
New Prohibitions:
(1) Agency self-investigation of research integrity complaints (all complaints referred to GAO).
(2) Classification of research findings to protect corporate interests, commercial interests, or agency reputation. Classification permitted only for genuine national security per EO 13526.
(3) Retaliation against researchers for internal or external disclosure of integrity concerns.
(4) Advisory committee voting by members with financial conflicts exceeding thresholds.
(5) Delay of public health finding publication beyond 30 days without GAO-approved extension.
Enforcement:
(1) GAO binding authority over all research integrity disputes with 90-day resolution target.
(2) Criminal penalties for intentional suppression of public health findings: up to 5 years imprisonment, $250,000 fine. Civil penalties up to $100,000 per day for ongoing suppression.
(3) Criminal penalties for revolving door violations: up to 2 years imprisonment, $50,000 fine, disgorgement.
(4) GAO annual audits of conflict disclosures, publication compliance, and advisory committee composition.
(5) Public dashboard displaying all conflict disclosures, publication timelines, and GAO case outcomes.
(6) Automatic disqualification from federal research funding for 5 years upon GAO finding of intentional misconduct.
Definitions:
Financial conflict of interest: Any financial relationship exceeding $5,000 annually between researcher/advisory member and entity affected by research findings, including employment, consulting, speaking fees, or equity holdings exceeding $10,000.
Independent scientist: Researcher with no funding, consulting, or employment from commercial entities in relevant field within preceding 5 years, and no equity holdings exceeding $10,000 in affected industries.
Genuine national security: Information causing identifiable damage to national defense or foreign relations per EO 13526, explicitly excluding embarrassment, corporate protection, civil liability shielding, or agency reputation.
Public health finding: Research conclusion with direct implications for human health, safety, or environmental exposure, including but not limited to drug safety, chemical toxicity, disease transmission, and food safety data.
Regulatory science: Research conducted by or for federal agencies that directly informs regulatory decisions, enforcement actions, or standard-setting.
Revolving door: Movement of federal researchers to private sector employment with entities they regulated, funded, or evaluated, or the reverse movement from private sector to federal research positions with authority over former employers.
What Changes
Before: Agencies self-investigate integrity complaints. Office of Research Integrity limited to PHS research. 47% of FDA advisory committee members have conflicts¹. No binding revolving door restrictions. No publication timeline for public health findings. Industry funds regulatory science with minimal disclosure. Whistleblower protections vary by agency.
After: GAO exclusive jurisdiction over all integrity disputes with binding authority. Government-wide conflict disclosure with $5,000 threshold. 3-year criminal revolving door restriction. 30-day publication deadline with 7-day automatic release failsafe. Industry funding prohibited for regulatory science conclusions. Advisory committee voting restricted to independent scientists. Unified whistleblower protections with qui tam incentives.
ROI
Costs:
| Item | 10-Year |
|---|---|
| GAO research integrity docket | $250M |
| Conflict disclosure system | $50M |
| Public repository infrastructure | $100M |
| Training and compliance | $100M |
| Total | $500M |
Savings:
| Item | Gross | Capture | Net |
|---|---|---|---|
| Avoided regulatory capture costs | $5B | 50% | $2.5B |
| Reduced litigation from suppressed findings | $2B | 60% | $1.2B |
| Improved research efficiency (reduced duplication) | $3B | 40% | $1.2B |
| Total | $10B | 49% | $4.9B |
Societal Benefits:
| Benefit | Annual | NPV (3%) | NPV (7%) |
|---|---|---|---|
| Faster public health interventions | $5B | $42.5B | $35B |
| Improved regulatory decision quality | $2B | $17B | $14B |
| Enhanced public trust in federal research | $1B | $8.5B | $7B |
| Total | $8B | $68B | $56B |
Summary:
| Category | 10-Year | Notes |
|---|---|---|
| Implementation Costs | $500M | Oversight infrastructure |
| Federal Budget Savings | $4.9B | Reduced regulatory capture |
| Net Federal Impact | $4.4B | Positive ROI |
| Societal Benefits | $68B | NPV at 3% (health outcomes) |
| Combined Net Benefit | $72.4B | Federal + societal value |
Confidence: MEDIUM - Regulatory capture costs difficult to quantify precisely. Societal benefits dependent on behavioral change in response to new requirements.
References
- JAMA Study on FDA Advisory Committee Financial Conflicts (2018)
- PLOS Medicine, "Publication Delay of Public Health Findings" (2020)
- Cochrane Review, "Industry Sponsorship and Research Outcomes" (2017)
- HHS OIG, "NIH Conflict of Interest Oversight" (2020)
- 15 U.S.C. § 3710 (Federal Technology Transfer Act)
- 42 C.F.R. Part 93 (Office of Research Integrity)
- 5 U.S.C. App. 2 (Federal Advisory Committee Act)
- 5 U.S.C. § 2302(b)(8) (Whistleblower Protection)
- 18 U.S.C. § 1001 (False Statements)
- Executive Order 13526 (Classified National Security Information)
- Chrysler Corp. v. Brown, 441 U.S. 281 (1979)
- Forsham v. Harris, 445 U.S. 169 (1980)
Change Log
2025-12-10 - Oversight Body Standardization: Changed enforcement body from Court of Federal Claims to GAO (GAO). Research integrity is regulatory in nature (rulemaking, disclosure requirements, conflict standards) and properly falls under GAO jurisdiction per Federal Oversight Consolidation framework. Court of Federal Claims handles procurement and property disputes.
2025-12-09 - Document Created: Split from Federal_Research_Lab_Consolidation.md. Research integrity, conflict of interest, revolving door, publication requirements, and whistleblower provisions consolidated here. Infrastructure consolidation provisions remain in Federal_Research_Lab_Consolidation.md.
2025-12-11 - Zero New Bodies Architecture: Updated oversight entity references per Federal Oversight Consolidation Act. Replaced proposed GAO divisions with existing infrastructure (GAO teams, DOJ OIG). No new bureaucratic entities created.